Antibody Tx Reduces Graft-vs-Host Post Stem Cell Transplant

Results for patients with acute leukemia

blood cells

THURSDAY, Jan. 7, 2016 (HealthDay News) -- Antibody therapy before stem cell transplant may benefit patients with acute leukemia, according to research published in the Jan. 7 issue of the New England Journal of Medicine.

The study included 168 leukemia patients treated at 27 different centers. The volunteers were randomly assigned to receive antihuman T-lymphocyte immune globulin (ATG) or not. After an average follow-up of two years, 32.2 percent of the patients given ATG had chronic graft-versus-host disease. But, 68.7 percent of patients who weren't given ATG had chronic graft-versus-host disease.

At two years, the survival rate was similar in patients who received ATG or didn't. But, the rate of survival in which they were free from chronic graft-versus-host disease and cancer recurrence was significantly better among patients given the antibody -- 36.6 versus 16.8 percent, the researchers found.

"Graft-versus-host disease is the most serious complication after stem cell transplantation," lead researcher Francesca Bonifazi, M.D., from the Institute of Hematology at Bologna University in Italy, told HealthDay. "Using [ATG] reduces the risk of complications of stem cell transplants without increasing the risk of leukemia recurrence and infections."

Full Text

Physician's Briefing